Standard Biotools (LAB) Income towards Parent Company (2010 - 2026)

Standard Biotools (LAB) has reported Income towards Parent Company for 17 consecutive years, with $141.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 5420.84% year-over-year to $141.7 million; the TTM figure through Mar 2026 stood at $106.2 million (up 237.62% YoY), while the FY2025 annual figure was -$58.8 million, up 57.05% from the prior year.
• Income towards Parent Company advanced to $141.7 million in Q1 2026 per LAB's latest filing, from $13.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $153.2 million in Q4 2022 and bottomed at -$76.3 million in Q1 2022.
• Historically, Income towards Parent Company has averaged -$3.5 million across 5 years, with a median of -$21.0 million in 2023.
• Annual changes were most pronounced in 2022 — Income towards Parent Company tumbled 305.96% — and 2026, when it soared 5420.84%.
• Standard Biotools' Income towards Parent Company stood at $153.2 million in 2022, then tumbled by 90.78% to $14.1 million in 2023, then slumped by 292.36% to -$27.2 million in 2024, then jumped by 151.16% to $13.9 million in 2025, then surged by 919.31% to $141.7 million in 2026.
• Business Quant data shows LAB's Income towards Parent Company at $141.7 million in Q1 2026, $13.9 million in Q4 2025, and -$31.7 million in Q3 2025.